Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 for mild to moderate Alzheimer's disease
NL-OMON53512Phase 2Recruiting
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- May 2023
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tertomotide in Alzheimer's disease (AD) (3 arms), sponsored by GemVax & KAEL Co., Ltd. Primary endpoints: Change from baseline in ADAS-Cog11 score at Week 52 and Safety and tolerability. Started May 2023; status: recruiting.
02
Drugs
tertomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON53512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53512.